A Single Dose, Randomized, Double-blind Crossover Comparison of Combivent CFC MDI and Albuterol HFA MDI in Patients With Moderate to Severe Persistent Asthma and Persistent Symptoms Despite Treatment With Inhaled Corticosteroids
- NCT00096616
- PHASE2
- INTERVENTIONAL
Last updated: 2013-11-01
Purpose of Trial
The purpose of this study is to demonstrate the superior bronchodilator efficacy of inhaled Combivent® CFC MDI vs. Albuterol HFA MDI in moderate to severe asthma patients.
This study is for people with
Asthma
Interventions being studied
Combivent® CFC MDI
Albuterol HFA MDI
Inclusion Criteria:
* Patient greater than or equal to 18 years of age,
* non-smokers,
* diagnosed with asthma, with an FEV1 less than or equal to 70 percent of predicted normal,
* stable use of Beta agonist
* daily use of inhaled steroids for one year
Exclusion Criteria:
* Patients with other significant diseases other than asthma, requiring oxygen,
* intubated within 5 years,
* asthma exacerbation within 6 weeks of trial,
* use of unstable doses (greater than 10 mg/day of prednisone or equivalent) of steroids,
* participating in another interventional trial
ELIGIBILITY
Gender: ALL
Age: 18+
Healthy Volunteers: No
27 Locations
Birmingham
620 South 20th Street, NHB 104
Alabama, United States
Birmingham
Cooper Green Hospital
Alabama, United States
Lakewood
Southern California Clinical Trials
California, United States
Palmdale
Boehringer Ingelheim Investigational Site
California, United States
Wheat Ridge
Boehringer Ingelheim Investigational Site
Colorado, United States
Norwalk
Norwalk Hospital
Connecticut, United States
Miami
University of Miami School of Medicine
Florida, United States
Panama City
Boehringer Ingelheim Investigational Site
Florida, United States
Coeur d'Arlene
Boehringer Ingelheim Investigational Site
Idaho, United States
River Forest
Boehringer Ingelheim Investigational Site
Illinois, United States
Olathe
Boehringer Ingelheim Investigational Site
Kansas, United States
Shreveport
LSU MC-Sheveport
Louisiana, United States
Auburn
Boehringer Ingelheim Investigational Site
Maine, United States
Baltimore
Johns Hopkins Asthma & Allergy
Maryland, United States
Boston
Brigham & Women's Hospital
Massachusetts, United States
Berlin
Boehringer Ingelheim Investigational Site
New Jersey, United States
Cherry Hill
Boehringer Ingelheim Investigational Site
New Jersey, United States
Manhasset
North Shore University Hospital
New York, United States
New York
NYU School of Medicine
New York, United States
Durham
Division of Pulmonary & Critical Care Medicine
North Carolina, United States
Winston-Salem
Wake Forest University, Center for Human Genomics
North Carolina, United States
Hershey
Penn State University, Hershey Medical Center
Pennsylvania, United States
Charleston
Boehringer Ingelheim Investigational Site
South Carolina, United States
Spartanburg
Spartanburg Medical Research
South Carolina, United States
Houston
Ben Taul General Hospital
Texas, United States
Tyler
University of Texas Health Center at Tyler
Texas, United States
Madison
University of Wisconsin Hospital
Wisconsin, United States
Primary Contact(s)
Boehringer Ingelheim
Data obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Learn more at
ClinicalTrials.gov